MediXall Group, Inc.
MDXL
$0.00
$0.000.00%
OTC PK
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -40.61% | -26.15% | 51.60% | 367.82% | 214.90% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -40.61% | -26.15% | 51.60% | 367.82% | 214.90% |
| Cost of Revenue | -26.87% | -27.15% | -39.69% | -33.90% | -17.43% |
| Gross Profit | 21.20% | 27.57% | 64.48% | 47.62% | 36.65% |
| SG&A Expenses | -75.46% | -67.22% | -75.48% | -22.39% | -14.48% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -63.76% | -57.48% | -64.57% | -16.98% | -15.21% |
| Operating Income | 65.50% | 59.85% | 72.66% | 23.09% | 19.63% |
| Income Before Tax | 129.05% | 50.39% | 60.16% | 18.40% | 16.22% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 129.05% | 50.39% | 60.16% | 18.40% | 16.22% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 129.05% | 50.39% | 60.16% | 18.40% | 16.22% |
| EBIT | 65.50% | 59.85% | 72.66% | 23.09% | 19.63% |
| EBITDA | 65.53% | 59.89% | 72.65% | 23.17% | 19.71% |
| EPS Basic | 118.42% | 50.60% | 60.38% | 25.00% | 23.23% |
| Normalized Basic EPS | 69.77% | 54.17% | 62.90% | 13.58% | 25.86% |
| EPS Diluted | 114.00% | 59.00% | 60.38% | 25.00% | 0.00% |
| Normalized Diluted EPS | 69.77% | 54.17% | 62.90% | 13.58% | 25.86% |
| Average Basic Shares Outstanding | 24.36% | 8.93% | 9.70% | 9.72% | 11.64% |
| Average Diluted Shares Outstanding | 24.36% | 8.93% | 9.70% | 9.72% | 11.64% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |